{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:44Z","timestamp":1787019584260,"version":"build-2736575974"},"reference-count":31,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP) (#NCT01142674) to develop a model to predict overall survival (OS) for the common nodal PTCL subtypes (PTCL-NOS, AITL, ALCL). The model was validated in an independent data set from Australian and Brazilian registries. 211 patients registered in the TCP between 2006-2018 were studied. The median age was 59 years (range 18-88) and median follow-up was 49 months. One hundred twenty-seven patients (78%) received anthracycline-based regimens, 5 patients (3%) radiotherapy alone (RT), 24 patients (15%) chemotherapy+RT. 5-year OS and PFS were 47% and 37%, respectively. Age &amp;gt;60 years, elevated LDH and low serum albumin were independent prognostic factors. The model identified 3 groups with low- (26%, score 0), intermediate- (41%, score 1), and high-risk (33%, score 2-3) with 5-year OS of 78% (95% confidence interval [95% CI], 29-127), 46% (95% CI, 24-68), and 25% (95% CI, 20-30), respectively (P &amp;lt; 0.001) and 5-year PFS of 66% (95% CI, 33-99), 37% (95% CI, 9-65), and 17% (95% CI, 9-25), respectively (P &amp;lt; 0.001). The model demonstrated greater discriminatory power than established prognostic indices and an analogous distribution and outcomes in the 3 groups in the validation cohort of 103 patients. The SALENTO Model (Limited Stage Peripheral T-Cell Lymphoma Prognostic Model) is an objective, simple and robust prognostic tool. The high-risk group has poor outcomes, comparable to advanced stage disease, and should be considered for innovative first-line approaches.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010037","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T15:19:56Z","timestamp":1683731996000},"page":"5047-5054","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network"],"prefix":"10.1182","volume":"7","author":[{"given":"Greg","family":"Hapgood","sequence":"first","affiliation":[{"name":"1Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-5806","authenticated-orcid":false,"given":"Monica","family":"Civallero","sequence":"additional","affiliation":[{"name":"2CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Stepanishyna","sequence":"additional","affiliation":[{"name":"3Kiev National Cancer Institute, Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie","family":"Vose","sequence":"additional","affiliation":[{"name":"4University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-3871","authenticated-orcid":false,"given":"Monica Elena","family":"Cabrera","sequence":"additional","affiliation":[{"name":"5Hematology Section, Hospital del Salvador, University of Chile, Santiago de Chile, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"6Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-5128","authenticated-orcid":false,"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[{"name":"7Division of Diagnostic Haematopathology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8097-9922","authenticated-orcid":false,"given":"Martina","family":"Manni","sequence":"additional","affiliation":[{"name":"2CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"8Department Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-3162","authenticated-orcid":false,"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"9Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Hitz","sequence":"additional","affiliation":[{"name":"10The Swiss Group for Clinical Cancer Research, Department of Oncology\/Haematology, Cantonal Hospital, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"11Medical Oncology, University of Manchester, Manchester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Dlouhy","sequence":"additional","affiliation":[{"name":"12Clinic Barcelona, Hospital Universitari, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-2578","authenticated-orcid":false,"given":"Carlos","family":"Chiattone","sequence":"additional","affiliation":[{"name":"13Santa Casa Medical School of Sao Paulo and Samaritan Hospital, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"14Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-869X","authenticated-orcid":false,"given":"Tetiana","family":"Skrypets","sequence":"additional","affiliation":[{"name":"15Hematology, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"16Hematology Division BMT and Cord Blood Bank Chaim Sheba Medical Center Tel-Hashomer, Ramat-Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"17Department of Haematology, Concord Hospital, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"2CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy"},{"name":"18Hematology, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"2CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"issue":"25","key":"2023091115440563200_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"2023091115440563200_bib2","volume-title":"WHO classification of tumours of haemopoietic and lymphoid tissues","author":"Swerdlow","year":"2017","edition":"Revised 4th ed"},{"issue":"1","key":"2023091115440563200_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5581\/1516-8484.20120013","article-title":"T-cell lymphomas in South america and europe","volume":"34","author":"Bellei","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"7","key":"2023091115440563200_bib4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2023091115440563200_bib5","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2023091115440563200_bib6","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3109\/10428194.2014.963078","article-title":"Survival in patients with limited-stage peripheral T-cell lymphomas","volume":"56","author":"Briski","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2023091115440563200_bib7","first-page":"4129","article-title":"The prognosis of limited stage peripheral T-cell lymphoma (PTCL): a population-based analysis and comparison to diffuse large B-cell lymphoma (DLBCL)","volume":"116","author":"Savage","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2023091115440563200_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ajh.26803","article-title":"Outcome of limited stage peripheral t-cell lymphoma after CHOP(-like) therapy: a population based study of 239 patients from the Nordic lymphoma epidemiology group","volume":"98","author":"Al-Mashhadi","year":"2023","journal-title":"Am J Hematol"},{"key":"2023091115440563200_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/5.suppl_2.S91","article-title":"A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin\u2019s lymphoma: preliminary results of SWOG-8516 (Intergroup 0067), the national high priority lymphoma study","volume":"5","author":"Fisher","year":"1994","journal-title":"Ann Oncol"},{"issue":"18","key":"2023091115440563200_bib10","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023091115440563200_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023091115440563200_bib12","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"2023091115440563200_bib13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2018.213512","article-title":"Systemic ALK-positive anaplastic large-cell lymphoma (ALCL): final analysis of an international, individual patient data study of 263 adults","volume":"104","author":"Sibon","year":"2019","journal-title":"Haematologica"},{"key":"2023091115440563200_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2023091115440563200_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hon.2846","article-title":"What's new in peripheral T-cell lymphomas","volume":"39","author":"Luminari","year":"2021","journal-title":"Hematol Oncol"},{"issue":"7","key":"2023091115440563200_bib16","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2023091115440563200_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. session type","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2023091115440563200_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med"},{"issue":"16","key":"2023091115440563200_bib19","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023091115440563200_bib20","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3109\/10428190903318311","article-title":"Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy","volume":"50","author":"Chihara","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023091115440563200_bib21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the international T cell project network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2023091115440563200_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15889","article-title":"Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma","volume":"186","author":"Burkart","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2023091115440563200_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00277-017-2958-1","article-title":"Impact of cachexia on outcomes in aggressive lymphomas","volume":"96","author":"Karmali","year":"2017","journal-title":"Ann Hematol"},{"issue":"21","key":"2023091115440563200_bib24","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease. international prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2023091115440563200_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma: The International NHL Prognostic Factors Project","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"2023091115440563200_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"2023091115440563200_bib27","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.15859","article-title":"Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas","volume":"186","author":"Ellin","year":"2019","journal-title":"Br J Haematol"},{"issue":"32","key":"2023091115440563200_bib28","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte Trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023091115440563200_bib29","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023091115440563200_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023091115440563200_bib31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/PAS.0000000000000188","article-title":"Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T\/NK-cell lymphomas. A North American PTCL study group project","volume":"38","author":"Hsi","year":"2014","journal-title":"Am J Surg Pathol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5047\/2077017\/blooda_adv-2023-010037-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/5047\/2077017\/blooda_adv-2023-010037-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:44:21Z","timestamp":1694432661000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/5047\/495768\/The-SALENTO-prognostic-model-for-limited-stage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010037","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}